Roche/Antisoma Ovarian Cancer Agent Phase III Failure Will Likely End Development
This article was originally published in The Pink Sheet Daily
Executive Summary
Radio-linked monoclonal antibody R-1549 did not meet primary endpoint of survival for ovarian cancer in pivotal SMART trial. Three additional cancer agents licensed by Roche under collaboration with Antisoma are in Phase I.
You may also be interested in...
Roche Phase III Success Rate Tops 70%, Double That Of Late '90s
The increase in rate of Phase III projects moving to registration stage over the last four years is largely due to positive outcomes from studies completed in 2004. Out of 12 major Phase III clinical trials completed over the last year, only pemtumomab in ovarian cancer did not meet its primary endpoint.
Pfizer Looks To Enter Oral Anti-Thrombotic Market Through Schering AG Deal
Company in-licenses Schering AG’s preclinical oral ADP receptor antagonist line; agents are targeted for chronic use in prophylaxis of arterial thrombosis and other CV events. Pfizer has one marketed anti-thrombotic, none in clinical development.